Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03810833 · ClinicalTrials.gov registry record · NA
Tolerability and Background Fluorescence of the MediBeacon Transdermal GFR Measurement System
A NA study of Acute Kidney Injury, sponsored by MediBeacon.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT03810833: Completed NA study of Acute Kidney Injury, sponsored by MediBeacon.
NCT03810833 is a NA study of Acute Kidney Injury that has completed, run by MediBeacon. The registered enrollment target is 12 participants, below the 2,331-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03810833, a NA study of Acute Kidney Injury, has completed, sponsored by MediBeacon.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to evaluate background fluorescence of participants of different ages, gender, and skin color. In addition, 48-hour tolerability of the sensor and adhesive will be evaluated.
Primary Outcome
Two separate Brilliance device sensors will be attached via standard adhesive pads to the left and right pectoralis major on each participant. Fluorescence measurements will be collected directly by the MediBeacon Transdermal GFR Measurement System Brilliance device, and will be continuously collected throughout the 48 hour study.
Conditions Studied
Interventions
- DEVICE Brilliance device sensor
Study Locations (1)
Missouri
- St. Louis Clinical Trials - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-09-16 |
| Est. Completion | 2019-09-23 |
| Phase | NA |
What the finished NCT03810833 record still lists
NCT03810833 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 2,331-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Acute Kidney Injury appearing as the primary indexed condition, and to 1 intervention - of which Brilliance device sensor is the first listed.
NCT03810833 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT03810833 about?
NCT03810833 is a clinical study titled "Tolerability and Background Fluorescence of the MediBeacon Transdermal GFR Measurement System". This study is designed to evaluate background fluorescence of participants of different ages, gender, and skin color. In addition, 48-hour tolerability of the sensor and adhesive will be evaluated.
What is the current status of trial NCT03810833?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2019-09-16. Estimated completion is 2019-09-23.
What conditions does trial NCT03810833 study?
This clinical trial studies the following conditions: Acute Kidney Injury.
What interventions are being tested in trial NCT03810833?
The interventions under investigation include: Brilliance device sensor (DEVICE).
Who is sponsoring clinical trial NCT03810833?
This trial is sponsored by MediBeacon, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03810833 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03810833's enrollment target sits among peer trials
12 72nd of 74 higher than 2 of 74 other Acute Kidney Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Kidney Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
RECRUITING · NA
-
Nafamostat Efficacy in Phase 3 Registrational CRRT Study
RECRUITING · NA
-
Initial Resuscitation for Acute Kidney Injury in Cirrhosis
RECRUITING · NA
-
CTSN Embolic Protection Trial
RECRUITING · NA
-
A Study of Facilitators and Barriers to Improve Acute Kidney Injury in Children Through Mobile Health Intervention
RECRUITING · NA
-
Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI